IMPORTANT SAFETY INFORMATION
Indication: METROGEL® 1% is indicated
for the topical treatment of the inflammatory lesions of rosacea. Adverse Events:
In controlled clinical studies, the most commonly reported adverse events (>2%)
in patients treated with METROGEL 1% were nasopharyngitis, upper respiratory tract
infection, and headache. Other adverse experiences reported when using topical metronidazole
include skin irritation, transient redness, metallic taste, tingling or numbness
of the extremities and nausea. Warnings/Precautions: METROGEL 1%
should not be used by patients who are allergic to metronidazole or any ingredient
in METROGEL 1%. Avoid contact of METROGEL 1% with the eyes as it may cause tearing.
METROGEL 1% should be used with caution in patients with evidence of, or a history
of, blood dyscrasia, and with patients taking blood thinning agents as they may
experience prolonged prothrombin times. METROGEL 1% treatment should be discontinued
if numbness or paresthesia of any extremity should occur.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch
or call 1-800-FDA-1088.